Lars Jøran Kjerpeseth’s research looks at the use of oral anticoagulants to prevent stroke in patients with atrial fibrillation.

MAIN RESULTS:

1. Prescription of novel oral anticoagulants increases fast in patients with atrial fibrillation.
2. Patients with previous stroke are more likely to get novel oral anticoagulants instead of warfarin.
3. Patients with heart failure and diabetes are more likely to get a warfarin prescription.

THESIS DEFENCE:

Thesis: Oral anticoagulation for stroke prevention in atrial fibrillation: Data from the Norwegian Prescription Database, the Norwegian Patient Registry and the Norwegian Cause of Death Registry
Candidate: Lars Jøran Kjerpeseth
Time: May 28, 2019 at 13:15
Place:St. Olavs Hospital, Medical Technical Research Center: Auditorium MTA
Link to university website (in Norwegian)

SUMMARY:

(1) 2015 was the first year the use of novel oral anticoagulants surpassed the use of warfarin in patients with atrial fibrillation in Norway. The new oral anticoagulants were introduced in Norway in 2011. A total of 129 285 patients with atrial fibrillation received a prescription for anticoagulant treament in Norway from 2011 to 2015, with a gradual increase throughout the period.

(2) In 2015, 86 % av all new users of oral anticoagulants received a prescription for one of the novel drugs. Atrial fibrillation patients with vascular disease, heart failure and diabetes were less likely to receive novel oral anticoagulants instead of warfarin. Women and patients with a previous stroke had increased likelihood of receiving novel oral anticoagulants.

REFERENCES:

(1) Kjerpeseth, L. J., Ellekjaer, H., Selmer, R., Ariansen, I., Furu, K., & Skovlund, E. (2017). Trends in use of warfarin and direct oral anticoagulants in atrial fibrillation in Norway, 2010 to 2015. European journal of clinical pharmacology, 73(11), 1417-1425.

(2) Kjerpeseth, L. J., Ellekjaer, H., Selmer, R., Ariansen, I., Furu, K., & Skovlund, E. (2018). Risk factors for stroke and choice of oral anticoagulant in atrial fibrillation. European journal of clinical pharmacology, 74(12), 1653-1662.